Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Janssen Presents Landmark Data From Invokana Study

Janssen’s Invokana became the only medicine in nearly 20 years and the first diabetes medicine ever to demonstrate a reduction in progression to end-stage renal failure in T2D patients with CKD.

Read More »

Novo Nordisk, Gilead team up to test NASH treatment

Novo Nordisk and Gilead Sciences will join forces on a clinical trial combining drugs from the two pharmaceutical firms to treat a progressive fatty liver disease known as NASH.

Read More »

NIH Begins Trial of Potential Universal Flu Vaccine

Scientists at the National Institutes of Health (NIH) launched a trial to examine a potential universal flu vaccine candidate, known as H1ssF_3928.

Read More »

ViiV Healthcare Announces 3-Year HIV Data for Juluca 2-Drug Combo

ViiV Healthcare presented three-year data from the SWORD 1 and 2 clinical trials in HIV.

Read More »

Exclusive: Astellas’ Xospata Provides Strong OS Benefits in Phase III Trial

Astellas Pharma’s blood cancer drug Xospata continues to show impressive results in the acute myeloid leukemia setting.

Read More »

AbbVie Cuts 178 Stemcentrx Employees Months After Rova-T Failure

AbbVie is slashing 178 jobs from the company’s Stemcentrx subsidiary in South San Francisco.

Read More »

Shares in Galapagos jump after arthritis drug results

Shares in Galapagos surged nearly 16 percent after the company reported positive results from several safety and efficacy trials of the Belgian drugmaker’s rheumatoid arthritis drug filgotinib.

Read More »

AstraZeneca pays up to $6.9 billion in Daiichi Sankyo cancer deal

AstraZeneca will pay up to $6.9 billion to work with Daiichi Sankyo on a hotly tipped experimental treatment for breast cancer, in a direct challenge to the world’s largest cancer drug maker Roche.

Read More »

Aldeyra’s eye drug meets main goal in late-stage study

Aldeyra Therapeutics Inc.’s drug reproxalap to treat a form of allergic reaction to the eye met the main goal in a late-stage trial, sending shares up more than 60 percent.

Read More »

Conatus Pharma Stock Craters After 3rd Failed NASH Trial

In an announcement short on details and trying to put a positive spin on things, San Diego-based Conatus Pharmaceuticals indicated its emricasan failed its Phase IIb ENCORE-NF clinical trial in patients with NASH.

Read More »

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

February 2019 Focus: Agenda 2019, Top 10 Pipelines To Watch, Value Of Pharmaceuticals, and more!

Subscribe

Ad Right Bottom